Skip Navigation

Bardia Nourbakhsh, M.D., M.A.S.

Bardia Nourbakhsh, M.D., M.A.S.

Headshot of Bardia Nourbakhsh
4.9out of 5
120 Ratings
  • Associate Program Director, Neuroimmunology and Neurological Infectious Disease Fellowship
  • Associate Professor of Neurology
Male

Languages: English, Farsi

Expertise

Epidemiology, Multiple Sclerosis, Neuroimmunology

Research Interests

Multiple Sclerosis

Locations

The Johns Hopkins Hospital

600 N. Wolfe Street
Baltimore, MD 21287 map

Background

Bardia Nourbakhsh, M.D., M.A.S., is an associate professor of neurology at Johns Hopkins University School of Medicine. Dr. Nourbakhsh is board-certified in neurology by the American Board of Psychiatry and Neurology. He practices out of The Johns Hopkins Hospital in Baltimore, Maryland.

Dr. Nourbakhsh has expertise in multiple sclerosis (MS) and neuroimmunology.

Dr. Nourbakhsh earned his medical degree from the Tehran University School of Medical Sciences and completed a residency in neurology at the University of Texas Southwestern Medical Center. He studied epidemiology, study design, and biostatistics, obtaining a Master of Advanced Studies degree in clinical research from the University of California, San Francisco School of Medicine, where he also completed a fellowship in MS and neuroimmunology.

In 2014, Dr. Nourbakhsh earned the American Brain Foundation Clinical Research Training Fellowship in MS, the National Multiple Sclerosis Society Sylvia Lawry Clinical Research Fellowship, the Fred Baskin Young Investigator Award, and the Teva Neuroscience Award for Academic Excellence.

In 2022, he was named a Harry Weaver Neuroscience Scholar by the National Multiple Sclerosis Society.

Dr. Nourbakhsh's research training focused on the design and execution of clinical trials and the use of biomarkers in MS. His current research interests include the comparative effectiveness studies of symptomatic and disease-modifying therapies in MS, as well as identifying new pathophysiologic mechanisms and therapeutic targets for MS-related fatigue. Dr. Nourbakhsh is the principal investigator of a randomized, double-blind clinical trial funded by the Department of Defense, which tests whether ketamine could be a treatment for MS fatigue. He has contributed to numerous publications, journal articles, abstracts and posters, and lectures. He is an ad hoc reviewer for Lancet Neurology, Annals of Neurology, Neurology, Neurology: Neuroimmunology and Neuroinflammation, Multiple Sclerosis Journal, and other journals. 

...read more

Titles

  • Associate Program Director, Neuroimmunology and Neurological Infectious Disease Fellowship
  • Associate Professor of Neurology

Departments / Divisions

Education

Degrees

  • MD; Tehran University School of Medical Sciences (2007)

Residencies

  • Neurology; University of Texas Southwestern Medical Center (2014)

Fellowships

  • University of California San Francisco School of Medicine (2017)

Board Certifications

  • American Board of Psychiatry And Neurology (Neurology) (2014)

Research & Publications

Research Summary

Dr. Nourbakhsh's research training focused on designing and executing clinical trials and using biomarkers in multiple sclerosis. His current research interests include the comparative effectiveness studies of symptomatic and disease-modifying therapies in multiple sclerosis and identifying new pathophysiologic mechanisms and therapeutic targets for multiple sclerosis fatigue.

Clinical Trial Keywords

Multiple Sclerosis

Clinical Trials

Dr. Nourbakhsh is the principal investigator of a randomized, double-blind clinical trial of ketamine for multiple sclerosis fatigue that is funded by the Department of Defense.

Selected Publications

View all on PubMed

Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. The Lancet Neurology 2021; 20: 38–48

Nourbakhsh B, Cordano C, Asteggiano C, Ruprecht K, Otto C, Rutatangwa A, Lui A, Hart J, Flanagan EP, James JA, Waubant E.  MS is rare in EBV-seronegative children with CNS inflammatory demyelination. ANN NEUROL 2021;89:1234-1239

Fitzgerald KC, Morris B, Soroosh A, et al. Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis–related fatigue. Multiple Sclerosis Journal. 2021;27(6):942-953

Nourbakhsh B, Mowry EM. Multiple Sclerosis Risk Factors and Pathogenesis. Continuum. 2019 Jun;25(3):596-610

Nourbakhsh B, Bhargava P, Tremlett H, Hart J, Graves J, Waubant E. Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. Ann Clin Transl Neurol. 2018 Sep 27;5(10):1211-1221.

Academic Affiliations & Courses

Graduate Program Affiliation

Associate Program Director, Neuroimmunology and Neurological Infectious Disease Fellowship

Activities & Honors

Honors

  • Harry Weaver Neuroscience Scholar, National Multiple Sclerosis Society, 2022
  • Clinical Research Training Fellowship in Multiple Sclerosis, American Brain Foundation
  • Sylvia Lawry Clinical Research Fellowship, National Multiple Sclerosis Society
  • Fred Baskin Young Investigator Award
  • Teva Neuroscience Award for Academic Excellence

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • 4.9 Provider Explained Things Clearly
  • 4.9 Provider Listened Carefully
  • 4.8 Provider Knew Medical History
  • 4.9 Provider Showed Respect
  • 4.9 Provider Spent Enough Time
  • 4.8 Overall Rating by Patient

Comments

4.9 out of 5 (120 Ratings, 35 Comments)
    Is this you? Edit Profile
    back to top button